Inversion deals by US and European clients, although tailing off, have dominated the corporate space and drove deal value through the roof in recent years, with this year's largest transaction involving an Irish
company so far being Mylan's $ 32.6 bn bid for Irish pharma company Perrigo Company, according to data provided by Merger
company so far being
Mylan's $ 32.6 bn bid for Irish
pharma company Perrigo Company, according to data provided by Merger
company Perrigo
Company, according to data provided by Merger
Company, according to data provided by Mergermarket.
Ideal
Companies: Any Pharmaceutical, Bio therapeutic, Medical Corporation:, Abbott, Acredo, Acorda, Allergan, Amgen, Amylin, Aptalis, Astellas, Astra Zeneca, Avanir, Aventis, Baxter, Bayer, Becton Dickinson, Biogen Idec, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centrix, Covidien, CSL Behring, Daichii Sankyo, Dainippon Sumitomo, Eisai, Eli Lilly, Endo
Pharma, Ferring
Pharma, Forest Laboratories, General Electric, Genentech, Genzyme, Glaxo Smith Kline, Hoffman - LaRoche, Hospira, InVentiv Health, Ironwood
Pharma, Johnson & Johnson, Medicis
Pharma, Medimmune, MedIsolv, Merck, Medtronic,
Mylan Inc., Norgenix, Novis
Pharma, Novo Nordisk, OctaPharma, Onyx
Pharma, Ortho - McNeil, Otsuka
Pharma, PDI, PDL BioPharma, Pfizer, Proctor & Gamble, Publicis, Purdue
Pharma, Purepac
Pharma, Quest Diagnostics, Lab Corps, Quintiles, Ranbaxy
Pharma, Regeneron
Pharma, Respa
Pharma, Roche Phaarma, Royalty
Pharma, Cypress Bioscience, Salix
Pharma, Sanofi - Aventis, Savient
Pharma, Shire
Pharma, Sigfreid USA, Spectrum
Pharma, Stryker Corp, Sunovion
Pharma, Takeda
Pharma, Teva
Pharma, UCB
Pharma, United Therapeutics, Zoetis Animal
Pharma, 3M
Pharma, Actavis
Pharma, Indeva
Pharma, Sunageva BioPharma, Dupont, plus any!